Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$218.40-0.8%$200.25$163.81▼$221.76$389.03B0.534.35 million shs4.42 million shsJNJJohnson & Johnson$178.10-0.2%$170.81$140.68▼$181.16$429.89B0.47.55 million shs7.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.77%+2.85%+8.46%+14.54%+12.24%JNJJohnson & Johnson-0.17%-0.05%+2.19%+13.51%+8.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$218.40-0.8%$200.25$163.81▼$221.76$389.03B0.534.35 million shs4.42 million shsJNJJohnson & Johnson$178.10-0.2%$170.81$140.68▼$181.16$429.89B0.47.55 million shs7.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.77%+2.85%+8.46%+14.54%+12.24%JNJJohnson & Johnson-0.17%-0.05%+2.19%+13.51%+8.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$217.10-0.60% DownsideJNJJohnson & Johnson 2.65Moderate Buy$176.29-1.02% DownsideCurrent Analyst Ratings BreakdownLatest JNJ and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $260.009/12/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $240.008/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/12/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$231.008/11/2025ABBVAbbViePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ABBVAbbVieDaiwa AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/7/2025ABBVAbbVieDaiwa Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$214.008/1/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$250.00 ➝ $255.008/1/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$216.00 ➝ $227.008/1/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$227.00 ➝ $236.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.85$14.81 per share14.75$1.90 per share114.95JNJJohnson & Johnson$88.82B4.83$13.10 per share13.60$29.69 per share6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10104.0015.621.426.45%699.66%13.64%10/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3519.0516.092.2725.00%32.49%13.00%10/14/2025 (Estimated)Latest JNJ and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.00%N/A312.38%53 YearsJNJJohnson & Johnson$5.202.92%N/A55.61%64 YearsLatest JNJ and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ and ABBV HeadlinesRecent News About These CompaniesJohnson & Johnson $JNJ Shares Sold by Swedbank ABSeptember 13 at 7:01 AM | marketbeat.comAG2R LA Mondiale Gestion D Actifs Makes New $18.79 Million Investment in Johnson & Johnson $JNJSeptember 13 at 6:53 AM | marketbeat.comGuinness Asset Management LTD Has $224.93 Million Stock Holdings in Johnson & Johnson $JNJSeptember 13 at 6:43 AM | marketbeat.comMaple Capital Management Inc. Purchases 1,748 Shares of Johnson & Johnson $JNJSeptember 13 at 6:43 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by First Long Island Investors LLCSeptember 13 at 6:15 AM | marketbeat.comBontempo Ohly Capital Mgmt LLC Purchases 13,649 Shares of Johnson & Johnson $JNJSeptember 13 at 6:06 AM | marketbeat.comModern Wealth Management LLC Raises Stake in Johnson & Johnson $JNJSeptember 13 at 5:37 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Raised to "Buy" at Wall Street ZenSeptember 13 at 2:26 AM | marketbeat.comJNJ Seeks EU Approval for Oral Psoriasis Drug IcotrokinraSeptember 12 at 12:40 PM | zacks.comJim Cramer Says Johnson & Johnson Stock Could Power Through $200 NextSeptember 12 at 10:51 AM | benzinga.comJohnson & Johnson $JNJ Shares Sold by Birmingham Capital Management Co. Inc. ALSeptember 12 at 7:14 AM | marketbeat.comSilicon Valley Capital Partners Buys 7,077 Shares of Johnson & Johnson $JNJSeptember 12 at 7:04 AM | marketbeat.comStrs Ohio Purchases Shares of 822,687 Johnson & Johnson $JNJSeptember 12 at 7:01 AM | marketbeat.com1,554 Shares in Johnson & Johnson $JNJ Purchased by GK Wealth Management LLCSeptember 12 at 7:00 AM | marketbeat.comJohnson & Johnson $JNJ Holdings Raised by Ellsworth Advisors LLCSeptember 12 at 6:52 AM | marketbeat.comIntrua Financial LLC Boosts Stake in Johnson & Johnson $JNJSeptember 12 at 6:44 AM | marketbeat.comAdvisors Capital Management LLC Purchases 43,664 Shares of Johnson & Johnson $JNJSeptember 12 at 6:32 AM | marketbeat.comJ&J Painting Recognized with 2026 Consumer Choice Award for Painting Contractor in WaterlooSeptember 12 at 6:00 AM | accessnewswire.comAAfter a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim CramerSeptember 11 at 9:03 PM | youtube.comYJohnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth KnowingSeptember 11 at 6:45 PM | zacks.comGuggenheim Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)September 11 at 5:33 PM | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025JNJ and ABBV Company DescriptionsAbbVie NYSE:ABBV$218.40 -1.82 (-0.83%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$218.28 -0.13 (-0.06%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$178.10 -0.40 (-0.22%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$177.79 -0.31 (-0.17%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
